Synthetic DNA Approach is Key to Startup’s New Drug
By Lisa Howard
The way Justin Siegel describes it, ordering synthetic DNA is almost as easy as ordering a pair of shoes online.
“You just type it in — or if the protein has been sequenced at one point, we can copy and paste — order it, and it shows up five days later.”
UC Davis chemist Justin Siegel is a co-founder of PvP Biologics. The company is developing a new treatment for celiac disease, an autoimmune disorder triggered by ingesting gluten. (UC Davis/Karin Higgins)
By Holly Ober
Two UC Davis graduates have started a company incubated in the TEAM manufacturing facility at the UC Davis Department of Biomedical Engineering.
Arshia Firouzi and Gurkern Sufi met in 2011 as Freshmen living in Tercero Dormitories at UC Davis and quickly became friends. Arshia majored in Electrical Engineering and Gurkern in Biotechnology, and they worked with the mentorship of Professor Marc Facciotti to explore their shared interest in the intersection of electronics and biology. In 2015 they won a VentureWell grant for a research project, which they pursued in TEAM’s Molecular Prototyping and Bioinnovation Laboratory. By the end of their project, they had come up with an idea that grew into a company that could usher in a new era for laboratories all over the world.